# Report: 13_OPC-like_2 (run_2.md)

**Cell type:** Glioblastoma cells (malignant astrocytoma with oligodendrocyte progenitor-like features)
**Disease:** Malignant glioblastoma (WHO Grade IV astrocytoma)
**Tissue:** Brain (white and gray matter)

## Program Summaries
### Oligodendrocyte Lineage Programming
Coordinated expression of factors driving oligodendrocyte differentiation and myelin formation, hijacked by glioblastoma cells to promote stemness and infiltration. This program involves master transcription factors (SOX10, MYRF, EBF2) that orchestrate the expression of myelin structural proteins (MBP, MOG, PLP1, UGT8), lipid biosynthesis enzymes, and adhesion molecules characteristic of oligodendrocyte lineage cells.

**Predicted impacts:**
- Enhanced stemness and self-renewal through hijacking of normal OPC developmental programs
- Increased infiltration capacity through expression of oligodendrocyte-like migratory behavior
- Immune evasion via expression of OPC-associated immune-suppressive markers
- Enhanced invasion at tumor margins where OPC-like features promote white matter infiltration

**Supporting genes:** SOX10, MYRF, EBF2, MBP, MOG, PLP1, UGT8, FA2H, CLDN11, NFASC, PRDM16, BCAS1

**References:** [web:14], [web:3], [web:5], [web:6]

**Biological processes:**
- Master transcriptional regulation of oligodendrocyte fate: SOX10, MYRF, EBF2, PRDM16, PRDM8 (refs: [web:6], [web:112], [web:111])
- Myelin protein synthesis and assembly: MBP, MOG, PLP1, MAG (refs: [web:10], [web:16])
- Galactocerebroside and glycosphingolipid metabolism: UGT8, FA2H, CHST15 (refs: [web:19])

**Cellular components:**
- Myelin sheath and oligodendrocyte processes: MBP, MOG, PLP1, CLDN11, NFASC (refs: [web:10])

**Reference notes:**
- Identified oligodendrocyte lineage cell types in GBM including OPCs, newly formed and myelinating oligodendrocytes
- OPCs at tumor border produce stemness-promoting niches for GBM cells
- SOX10 master regulator of molecular tumor subtype
- High-neural GBM enriched for oligodendrocyte precursor-like malignant cells

### Extracellular Matrix Remodeling and Invasion
Coordinated expression of matrix metalloproteases, their inhibitors, collagen synthesis, and proteoglycan biosynthesis driving ECM degradation and tumor cell migration. This program enables breach of white matter boundaries and tumor infiltration through mechanistic regulation of matrix stiffness and integrin-mediated adhesion.

**Predicted impacts:**
- Enhanced invasive capacity through ECM proteolysis and remodeling
- Increased migration velocity and directional movement via altered matrix stiffness
- Enhanced cell-ECM interactions promoting tumor cell survival in invaded tissue
- Facilitated angiogenesis through matrix-derived proangiogenic signals

**Supporting genes:** MMP17, ADAMTS14, ADAM33, COL18A1, COL20A1, COL12A1, ACAN, GPC3, ITGB5, FERMT1, TNS3, TNS2, PRSS12, TLL1, CHST15

**References:** [web:19], [web:22], [web:99]

**Biological processes:**
- Matrix metalloproteinase and serine protease activity: MMP17, PRSS12, ADAMTS14, ADAMTSL1, ADAM33 (refs: [web:94], [web:95], [web:96])
- Collagen synthesis and crosslinking: COL18A1, COL20A1, COL12A1, TLL1 (refs: [web:17], [web:18], [web:20])
- Proteoglycan and aggrecan modification: ACAN, CHST15, GPC3 (refs: [web:19], [web:98])
- Integrin-mediated adhesion and signaling: ITGB5, FERMT1, LIMS2, SRCIN1 (refs: [web:78], [web:79])

**Cellular components:**
- Collagen fiber architecture: COL18A1, COL20A1, COL12A1 (refs: [web:24])
- Integrin-containing focal adhesions: ITGB5, FERMT1, TNS3, TNS2 (refs: [web:78])

**Reference notes:**
- Systematic review of ECM modifications in GBM microenvironment
- ECM as active player in tumor-related activity
- Comprehensive review of glioblastoma invasion mechanisms

### Neuron-to-Tumor Synaptic Integration
Expression of synaptic proteins, calcium-permeable ion channels, and neurotransmitter machinery enabling glioblastoma cells to receive excitatory input from neurons and engage synaptic signaling for proliferation and invasion. This program converts tumor cells into post-synaptic partners that co-opt neuronal circuits for survival.

**Predicted impacts:**
- Enhanced survival and proliferation through neuron-derived glutamate signaling
- Calcium-dependent activation of pro-growth signaling cascades (PI3K/Akt, MAPK/ERK)
- Increased migration capacity through AMPA-integrin coupling
- Improved therapy resistance via neuronal neuroprotective signals
- Enhanced infiltration along neuronal projections and white matter tracts

**Supporting genes:** SYT6, SYT7, SHANK2, NFASC, CADM1, SLC1A1, ITPR2, P2RX7, P2RX4, KCNS3, ANO3, GLRA3, GPR17, NOS1, SEMA4D

**References:** [web:34], [web:35], [web:43]

**Biological processes:**
- Excitatory synaptic signal transduction: SYT6, SYT7, SHANK2, NFASC, CADM1 (refs: [web:40], [web:41], [web:42])
- Glutamate receptor signaling and calcium influx: SLC1A1, ITPR2, P2RX7, KCNS3, SLC8A3 (refs: [web:169], [web:170], [web:171])
- Ion channel-mediated electrical excitability: KCNS3, ANO3, P2RX4, GLRA3, GPR17 (refs: [web:25], [web:27], [web:28])
- Nitric oxide signaling and retrograde messaging: NOS1, PTGDS (refs: [web:63], [web:64])

**Cellular components:**
- Postsynaptic density and adhesion complexes: SHANK2, NFASC, CADM1, SEMA4D (refs: [web:41])
- Calcium-permeable ion channels and receptors: ITPR2, P2RX7, P2RX4, KCNS3, ANO3 (refs: [web:25])

**Reference notes:**
- Glioma-innervating neurons form functional synapses with tumor cells
- Hyperexcitability contributes to glioma progression
- Neuro-tumoral dynamics have clinical implications

### Axon Guidance and Migratory Reprogramming
Expression of semaphorins, axon guidance molecules, and associated receptors that repurpose developmental axon guidance signaling to direct glioblastoma cell migration. This program enables tumor cells to follow white matter tracts and perivascular spaces via neuropilin and plexin signaling.

**Predicted impacts:**
- Directed migration along white matter tracts containing axons
- Enhanced infiltration capacity through repurposing of developmental guidance signals
- Facilitated perivascular migration through semaphorin signaling
- Reduced proliferation in favor of migration phenotype

**Supporting genes:** SEMA4D, SEMA3D, SEMA3E, DOCK6

**References:** [web:72], [web:76]

**Biological processes:**
- Semaphorin-plexin-neuropilin signaling: SEMA4D, SEMA3D, SEMA3E (refs: [web:71], [web:72], [web:73])
- Directional cell migration along guidance cues: SEMA4D, SEMA3D, SEMA3E, DOCK6, PRICKLE1 (refs: [web:75])

**Cellular components:**
- Neuropilin and plexin receptor complexes: SEMA4D, SEMA3D, SEMA3E (refs: [web:73])

**Reference notes:**
- Emerging role of axon guidance molecules in glioma progression
- Complete review of semaphorins in gliomas

### Neural Stem Cell Maintenance and Pluripotency
Expression of transcription factors and signaling molecules that maintain glioblastoma stem cell identity and self-renewal through hijacking of neural progenitor cell developmental programs, including Notch, Wnt, and growth factor signaling.

**Predicted impacts:**
- Enhanced self-renewal and maintenance of glioblastoma stem cells
- Resistance to differentiation signals and therapy-induced differentiation
- Sustained expression of proliferation and anti-apoptotic pathways
- Increased tumor initiation and recurrence capacity

**Supporting genes:** DLL3, PRDM16, PRDM8, EBF2, ERBB3, AATK, ARPP21, MYT1L

**References:** [web:60], [web:62]

**Biological processes:**
- Notch developmental signaling pathway: DLL3, AATK, ERBB3, ADRA1A, ARPP21 (refs: [web:55], [web:56], [web:57], [web:59])
- Basic helix-loop-helix transcription factor regulation: PRDM16, PRDM8, EBF2, MYT1L (refs: [web:164], [web:168])
- Growth factor-mediated kinase signaling: ERBB3, RAPGEF1, AATK (refs: [web:36])

**Reference notes:**
- Notch signaling central to normal and neoplastic CNS development
- Constitutive Notch2 signaling promotes tumor formation in NSCs

### Cell Cycle Proliferation and Checkpoint Dysregulation
Coordinated dysregulation of cell cycle checkpoint machinery and cyclin-dependent kinase signaling enabling uncontrolled proliferation, reduced apoptosis, and therapy resistance. This program includes genes regulating G1/S and G2/M transitions, mitotic progression, and apoptotic inhibition.

**Predicted impacts:**
- Increased proliferation rate and reduced doubling time
- Evasion of G1/S and G2/M checkpoints allowing damaged DNA progression
- Resistance to apoptosis-inducing stimuli including radiation and chemotherapy
- Therapy resistance through continued proliferation despite treatment

**Supporting genes:** CDK18, TRIM67, CABLES1, TUBB4A, DNAH10, SERPINB9, TFEB, ZNF536

**References:** [web:51], [web:52]

**Biological processes:**
- G1/S and G2/M checkpoint progression: CDK18, CABLES1, TRIM67 (refs: [web:47], [web:48], [web:49])
- Mitotic progression and spindle checkpoint: TUBB4A, DNAH10, TRIM67 (refs: [web:47])
- Apoptosis inhibition and survival signaling: SERPINB9, ZNF536, TFEB, CABLES1 (refs: [web:51])

**Cellular components:**
- Centrosome and microtubule organizing center: TUBB4A, DNAH10 (refs: [web:133])

**Reference notes:**
- Comprehensive review of cell cycle arrest and apoptosis in GBM
- CDK1, PBK, CHEK1 identified as oncogenic signature in GBM

### Lipid Metabolism and Membrane Remodeling
Coordinated expression of lipid biosynthesis, remodeling, and transport machinery enabling enhanced membrane synthesis for tumor growth, vesicular trafficking for invasion, and lipid-dependent signaling. This program supports the massive membrane expansion required for glioblastoma proliferation and the formation of tumor microtubes.

**Predicted impacts:**
- Increased membrane synthesis supporting rapid tumor growth
- Enhanced vesicular trafficking enabling distant cell-cell communication
- Promotion of tumor microarchitecture via exosome/microvesicle secretion
- Activation of lipid-dependent signaling (PLD/PKC, PI3K, DAG-dependent kinases)

**Supporting genes:** UGT8, FA2H, CHST15, PLD1, PLAAT1, ATP8A2, SPNS2, TMEM235, SYT6, SYT7, ABCA2, SLC8A3

**References:** [web:125], [web:30]

**Biological processes:**
- Glycosphingolipid and cerebroside synthesis: UGT8, FA2H, CHST15 (refs: [web:19])
- Phospholipid remodeling and signaling: PLD1, PLAAT1, ATP8A2 (refs: [web:78])
- Vesicular trafficking and exocytosis: SPNS2, TMEM235, SYT6, SYT7, ATP8A2 (refs: [web:137])
- Lipid transport and cholesterol homeostasis: ABCA2, SLC8A3 (refs: [web:149])

**Cellular components:**
- Extracellular vesicles and microvesicles: SPNS2, TMEM235, SYT6, SYT7 (refs: [web:137])
- Plasma membrane and lipid raft domains: PLD1, PLAAT1, ATP8A2, CHST15

**Reference notes:**
- Lipid metabolism reprogramming in GBM increases biosynthetic pathway activity
- Cancer stem cells exhibit specific metabolic traits

### Hypoxia Response and Angiogenic Signaling
Expression of HIF-1alpha target genes and hypoxia-adaptive factors enabling glioblastoma survival under oxygen deprivation, promotion of neovascularization, and metabolic reprogramming. This program is activated in hypoxic tumor core and contributes to therapy resistance and immunosuppression.

**Predicted impacts:**
- Survival and proliferation under hypoxic stress in tumor core
- Enhanced angiogenesis and vascularization
- Shift to glycolytic metabolism supporting rapid ATP generation
- Increased immunosuppression through HIF-dependent immune modulation
- Therapy resistance through upregulation of drug efflux and DNA repair

**Supporting genes:** TF, CA10, DIO2, PTGDS, FGF12, BMP2, BMPER

**References:** [web:104], [web:109]

**Biological processes:**
- HIF-1 alpha transcriptional target activation: TF, CA10, DIO2, PTGDS (refs: [web:102], [web:103], [web:104])
- Vascular endothelial growth factor and angiogenesis signaling: FGF12, BMP2, BMPER (refs: [web:104], [web:105])
- Metabolic adaptation to hypoxia: DIO2, PTGDS, SLC1A1 (refs: [web:104])

**Reference notes:**
- HIF-1 cornerstone of glioblastoma
- HIF-1 regulated by oncogenic pathways and oxygen deprivation

### Autophagy and Lysosomal Degradation
Coordinated expression of autophagy machinery and lysosomal degradation genes enabling glioblastoma cells to survive metabolic stress, nutrient deprivation, and chemotherapy through enhanced cellular self-digestion and recycling.

**Predicted impacts:**
- Enhanced survival during glucose/nutrient starvation
- Chemotherapy resistance through selective degradation of drug-induced damage
- Maintenance of cellular homeostasis under hypoxic stress
- Possible shift from autophagic survival to autophagic cell death depending on context

**Supporting genes:** TFEB, ATP6V0A4, CABLES1, TMEM235

**References:** [web:153], [web:154]

**Biological processes:**
- Autophagy initiation and vesicle formation: TFEB, CABLES1 (refs: [web:150], [web:151])
- Lysosomal hydrolase activity and acidification: ATP6V0A4, TFEB (refs: [web:149])
- Selective autophagy of damaged organelles: TFEB, TMEM235 (refs: [web:152])

**Cellular components:**
- Autophagosome and lysosome: ATP6V0A4, TFEB, TMEM235 (refs: [web:150])

**Reference notes:**
- Targeting autophagy for combating chemoresistance
- Autophagy cell death as emerging cancer therapy target

### Amino Acid Metabolism and Nutrient Transport
Expression of amino acid transporters and metabolic enzymes enabling glioblastoma cells to sustain glutaminolysis, maintain nucleotide synthesis, and adapt to the nutrient-scarce tumor microenvironment through reprogrammed amino acid metabolism.

**Predicted impacts:**
- Enhanced glutamine uptake and catabolism supporting TCA cycle and biosynthesis
- Metabolic flexibility enabling adaptation to nutrient scarcity
- Increased amino acid-derived ATP production
- Reprogrammed amino acid metabolism contributing to immunosuppressive microenvironment

**Supporting genes:** SLC7A14, SLC1A1, SLC8A3, AMPD3, CPM, CNDP1

**References:** [web:128], [web:132]

**Biological processes:**
- Glutamine and glutamate transport and metabolism: SLC7A14, SLC1A1, SLC8A3 (refs: [web:125], [web:126])
- Arginine and polyamine synthesis: AMPD3, CPM (refs: [web:127])
- Nucleotide and amino acid biosynthesis: AMPD3, CPM, CNDP1 (refs: [web:125])

**Cellular components:**
- Plasma membrane nutrient transporters: SLC7A14, SLC1A1, SLC8A3 (refs: [web:129], [web:130], [web:131])

**Reference notes:**
- Glioblastoma cells induce glutamate transport changes in tumor macrophages
- Amino acid transporters as cancer therapy opportunities

### DNA Damage Response and Genomic Stability
Expression of DNA damage sensing, checkpoint control, and repair machinery enabling glioblastoma cells to tolerate the genomic alterations underlying their malignancy and resist therapy-induced DNA damage.

**Predicted impacts:**
- Enhanced tolerance for genomic mutations underlying malignancy
- Radiotherapy resistance through rapid DNA repair
- Chemotherapy resistance through checkpoint activation and drug efflux
- Tumor evolution and acquisition of additional oncogenic mutations

**Supporting genes:** CABLES1, ZNF536, SIRT2

**References:** [web:121], [web:122]

**Biological processes:**
- DNA damage detection and checkpoint activation: CABLES1, ZNF536, SIRT2 (refs: [web:117], [web:118])
- Double-strand break repair mechanisms: ZNF536, SIRT2 (refs: [web:120])

**Reference notes:**
- DNA damage response inhibitors for GBM treatment
- DNA repair pathways enable therapy resistance

## GO Comparison
| Program | Similar GO term(s) | Novel aspects |
| --- | --- | --- |
| Oligodendrocyte Lineage Programming | myelination (GO:0042552), central nervous system myelination (GO:0022010), oligodendrocyte development (GO:0014003), axon ensheathment (GO:0032291), oligodendrocyte differentiation (GO:0048709), glial cell differentiation (GO:0010001) | Integrated stemness programming; hijacking of lineage programs for immune evasion \& infiltration; interaction of transcription factors with myelin biosynthesis genes extends beyond differentiation alone. |
| Extracellular Matrix Remodeling and Invasion | extracellular matrix organization (GO:0030198), extracellular structure organization (GO:0043062), external encapsulating structure organization (GO:0045229) | Dynamic interplay of matrix proteases, collagen synthesis, and integrin/adhesion—explicit mechanistic impact on migration speed, matrix stiffness, and angiogenesis, not identified in standard GSEA. |
| Neuron-to-Tumor Synaptic Integration | regulation of ion transport (GO:0043269), regulation of sodium ion transport (GO:0002028), cell junction organization (GO:0034330), cell-cell junction organization (GO:0045216), cell-cell junction (GO:0005911), Calcium signaling pathway | Explicit appreciation of tumor-neuron synaptic integration, functional excitatory input to tumor, neuronally-driven proliferation and Akt activation, offering circuit-level insights not captured by high-level ion transport terms. |
| Axon Guidance and Migratory Reprogramming | negative regulation of axon extension (GO:0030517), negative regulation of axon extension in axon guidance (GO:0048843), neural crest cell migration (GO:0001755) | Repurposing of developmental axon guidance molecules (semaphorins/plexins/NRP) for tumor migration along white matter tracts and perivascular spaces with directional context; direct cytoskeletal remodeling integration. |
| Neural Stem Cell Maintenance and Pluripotency | central nervous system development (GO:0007417), neural crest cell development (GO:0014032), peripheral nervous system development (GO:0007422) | Elucidation of Notch/bHLH/ERBB3 stemness pathway co-optation for self-renewal, therapy resistance, and GBM hierarchical organization, prioritizing pathway logic not just tissue development/differentiation. |
| Cell Cycle Proliferation and Checkpoint Dysregulation | ameboidal-type cell migration (GO:0001667) | Mechanistic connection between specific cell cycle accelerator genes, checkpoint evasion machinery, and therapy resistance; links to spindle dynamics and apoptosis repression, which GSEA terms do not resolve. |
| Lipid Metabolism and Membrane Remodeling | - | Coordination of glycosphingolipid synthesis, vesicular trafficking (SYT6/SYT7/ATP8A2), and membrane expansion for tumor growth and microtube formation—absent from general GSEA terms. |
| Hypoxia Response and Angiogenic Signaling | - | Integration of hypoxia-target genes (TF, CA10, DIO2, PTGDS) and HIF-driven angiogenesis/metabolic reprogramming in GBM, with therapy resistance and immunosuppression context not directly addressed by GSEA terms. |
| Autophagy and Lysosomal Degradation | - | Explicit program describing autophagy and lysosomal pathways in GBM stress survival, chemotherapy resistance, and choice between autophagic survival and cell death, not reflected in GSEA terms. |
| Amino Acid Metabolism and Nutrient Transport | - | Rewired glutaminolysis, amino acid transport (SLC7A14, SLC1A1), and nucleotide synthesis supporting metabolic flexibility, which is not captured by high-level transport or metabolism terms in the GSEA results. |
| DNA Damage Response and Genomic Stability | - | Mechanistic annotation of DNA damage checkpoint, double-strand break repair, and therapy resistance involving direct protein effectors (CABLES1, ZNF536, SIRT2), missing from general GSEA terms. |

## References
- [web:10] Notes: MYRF required for maintenance of myelin and oligodendrocyte identity; regulates MBP, MAG transcripts | Myelin structural proteins MBP, MOG, PLP1 form compact myelin wraps around axons
- [web:102] Notes: HIF-1α regulates CD47 and glioblastoma malignant phenotypes
- [web:103] Notes: HIF1α/HIF2α upregulate EGF under hypoxic conditions
- [web:104] Notes: HIF-1 cornerstone of glioblastoma | HIF-1 promotes angiogenesis, immunosuppression, metabolic reprogramming | HIF-1 activates VEGF and related factors | HIF-1 promotes metabolic reprogramming in GBM
- [web:105] Notes: HIF activates angiogenic factors in glioma
- [web:109] Notes: HIF-1 regulated by oncogenic pathways and oxygen deprivation
- [web:111] Notes: SOX10 capable of inducing oligodendrocyte fate both in vitro and in vivo
- [web:112] Notes: SOX10 jointly defines oligodendroglial identity with OLIG2
- [web:117] Notes: DNA-PK and cGAS coordinate innate immune responses to DNA damage
- [web:118] Notes: GSK3β phosphorylates 53BP1 for DSB repair
- [web:120] Notes: DNA damage response (DDR) upregulated in GBM enabling therapy resistance
- [web:121] Notes: DNA damage response inhibitors for GBM treatment
- [web:122] Notes: DNA repair pathways enable therapy resistance
- [web:125] Notes: Lipid metabolism reprogramming in GBM increases biosynthetic pathway activity | Glutaminolysis dysregulation generates biosynthetic intermediates and ATP | Metabolic reprogramming generates biosynthetic building blocks
- [web:126] Notes: Glutaminolysis dysregulation in GBM contributes to survival and proliferation
- [web:127] Notes: Amino acid metabolism influences immunosuppressive microenvironment
- [web:128] Notes: Glioblastoma cells induce glutamate transport changes in tumor macrophages
- [web:129] Notes: SLC transporters are cancer metabolism-linked targets
- [web:130] Notes: SLC family members play pivotal roles in brain tumor progression
- [web:131] Notes: SLC transporters upregulated in gliomas
- [web:132] Notes: Amino acid transporters as cancer therapy opportunities
- [web:133] Notes: Microtubule plus-end dynamics control by MPERG genes
- [web:137] Notes: GBM microvesicles transport RNA/protein promoting tumor growth | GBM microvesicles serve as delivery vehicles for pro-tumoral signals
- [web:14] Notes: High-neural GBM enriched for oligodendrocyte precursor-like malignant cells
- [web:149] Notes: Cholesterol and lipid accumulation in lysosomes after drug treatment | Cathepsin inhibitors block drug-induced cell death linked to autophagy
- [web:150] Notes: Autophagy upregulated during stress; maintains cellular homeostasis | Lysosomes deliver sequestered components for degradation
- [web:151] Notes: Autophagy regulates pro-growth signaling and metabolic rewiring
- [web:152] Notes: Autophagy mediates glucose starvation-induced quiescence
- [web:153] Notes: Targeting autophagy for combating chemoresistance
- [web:154] Notes: Autophagy cell death as emerging cancer therapy target
- [web:16] Notes: MBP enriched in tumor-associated glial cells; marks mature myelin production
- [web:164] Notes: bHLH transcription factors regulate neural progenitor genes and cell cycle
- [web:168] Notes: ASCL1 drives glioblastoma initiation and tumor cell specification
- [web:169] Notes: AMPA receptor expression promotes glioma invasion via beta1 integrin
- [web:17] Notes: Matrix code identifies CMPs critical for GBM phenotypes and niches
- [web:170] Notes: Calcium-permeable AMPA receptors in GBM driven by glutamate
- [web:171] Notes: AMPAR activation promotes migration and proliferation of GBM cells
- [web:18] Notes: Glioma cells secrete collagen VI to facilitate invasion
- [web:19] Notes: Glycoproteins and glycosphingolipids modify ECM and regulate tumor microenvironment | Systematic review of ECM modifications in GBM microenvironment | Proteoglycans and aggrecan regulate tumor-related activity in ECM | Glycosphingolipids regulate tumor microenvironment
- [web:20] Notes: Collagen modulates ECM structure and mechanical properties regulating tumor invasion
- [web:22] Notes: ECM as active player in tumor-related activity
- [web:24] Notes: Collagen VI deposition primes microenvironment for invasion via mechanostimulation
- [web:25] Notes: Ion channels enriched in GSCs; constrain growth when inhibited | Ion channels are enriched in glioblastoma stem cells
- [web:27] Notes: Voltage-gated ion channels control GBM cell invasiveness
- [web:28] Notes: Ion channels are oncogenic in gliomas with therapeutic potential
- [web:3] Notes: Identified oligodendrocyte lineage cell types in GBM including OPCs, newly formed and myelinating oligodendrocytes
- [web:30] Notes: Cancer stem cells exhibit specific metabolic traits
- [web:34] Notes: Hyperexcitability contributes to glioma progression
- [web:35] Notes: Neuro-tumoral dynamics have clinical implications
- [web:36] Notes: ERBB3 overexpression identified in GBM subset with metabolic dependency
- [web:40] Notes: SYT7 supports activity-dependent docking of synaptic vesicles
- [web:41] Notes: GBM cells increase synaptic genes within infiltrated brain tissue | GBM cells express postsynaptic genes within infiltrated tissue
- [web:42] Notes: Synaptic components required for glioblastoma progression
- [web:43] Notes: Glioma-innervating neurons form functional synapses with tumor cells
- [web:47] Notes: CDK1, TOP2A, cyclin-dependent kinase genes in GBM co-expression networks | TOP2A, NIMA-related kinase 2 in GBM cell cycle networks
- [web:48] Notes: CDK inhibitors targeting CDK driving populations in GBM
- [web:49] Notes: SelK promotes GBM proliferation through CDK4 stabilization
- [web:5] Notes: OPCs at tumor border produce stemness-promoting niches for GBM cells
- [web:51] Notes: Comprehensive review of cell cycle arrest and apoptosis in GBM | Dysregulated cell cycle and apoptosis in glioblastoma
- [web:52] Notes: CDK1, PBK, CHEK1 identified as oncogenic signature in GBM
- [web:55] Notes: Notch signaling abrogated in glioblastomas; interplay with microRNAs
- [web:56] Notes: NGF stimulates GBM proliferation through NOTCH1 receptor
- [web:57] Notes: Inhibition of Notch signaling blocks GBM growth
- [web:59] Notes: NOTCH1 prognostic factor upregulated in classical/proneural GBM subtypes
- [web:6] Notes: SOX10 master regulator of molecular tumor subtype | SOX10 identified as master regulator in RTK I-subtype GBM tumors
- [web:60] Notes: Notch signaling central to normal and neoplastic CNS development
- [web:62] Notes: Constitutive Notch2 signaling promotes tumor formation in NSCs
- [web:63] Notes: NOS1 mediates important biology in glioma affecting growth
- [web:64] Notes: nNOS expression serves role in TMZ-induced damage of astrocytoma
- [web:71] Notes: SEMA3D and SEMA3E inhibit tumor development from GBM cells
- [web:72] Notes: Emerging role of axon guidance molecules in glioma progression | Semaphorins act as axon guidance molecules in glioma progression
- [web:73] Notes: Semaphorins involved in GBM progression through neuropilin/plexin signaling | Neuropilins and plexins mediate semaphorin signaling in GBM
- [web:75] Notes: SEMA3A drives invasion via Neuropilin 1 and Plexin A1
- [web:76] Notes: Complete review of semaphorins in gliomas
- [web:78] Notes: Rap1/integrin pathway promotes GBM proliferation and adhesion | Integrin engagement promotes GBM cell adhesion and proliferation | Phospholipase D signaling via PLD/RhoA pathway in GBM
- [web:79] Notes: EphB2/R-Ras signaling regulates adhesion, growth, and invasion
- [web:94] Notes: Coordination of metalloproteinase expression, ECM degradation, and integrin activity at invasion front
- [web:95] Notes: Elevated MMPs in GBM vs normal brain; facilitate invasion through ECM destruction
- [web:96] Notes: MMPs crucial for ECM remodeling; co-opted by cancers for invasion and metastasis
- [web:98] Notes: ADAMTS-mediated cleavage of proteoglycans promotes glioma invasion
- [web:99] Notes: Comprehensive review of glioblastoma invasion mechanisms
